To assess drug efficacy in vivo, tumor growth was monitored in mice bearing subcutaneous ALK-F1174L Kelly xenografts and treatment was assessed using two different dosing protocols, with high- or low-dose regimens of TNO155, lorlatinib, or combination (Table 2). This evidence concerns the gene ALK and neoplasm.